Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy

W. C. Nichols; L. K. Kvols; J. N. Ingle; J. H. Edmonson; D. L. Ahmann; J. Rubin; M. J. O'Connell

Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy

W. C. Nichols, L. K. Kvols, J. N. Ingle, J. H. Edmonson, D. L. Ahmann, J. Rubin, M. J. O'Connell

Medical Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.

Original language	English (US)
Pages (from-to)	837-839
Number of pages	3
Journal	Cancer Treatment Reports
Volume	62
Issue number	5
State	Published - Dec 1 1978

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{7e6c7cb1f2cc4b49b853aed6d51ddcc2,

title = "Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy",

abstract = "The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.",

author = "Nichols, {W. C.} and Kvols, {L. K.} and Ingle, {J. N.} and Edmonson, {J. H.} and Ahmann, {D. L.} and J. Rubin and O'Connell, {M. J.}",

year = "1978",

month = dec,

day = "1",

language = "English (US)",

volume = "62",

pages = "837--839",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy

AU - Nichols, W. C.

AU - Kvols, L. K.

AU - Ingle, J. N.

AU - Edmonson, J. H.

AU - Ahmann, D. L.

AU - Rubin, J.

AU - O'Connell, M. J.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.

AB - The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018098168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018098168&partnerID=8YFLogxK

M3 - Article

C2 - 657166

AN - SCOPUS:0018098168

SN - 0027-8874

VL - 62

SP - 837

EP - 839

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 5

ER -

Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this